Drug Trial Radar · NCT01245179
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 2010
Primary completion
Dec 31, 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Abdullah KutlarAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Secura Bio, Inc.
- First posted
- Nov 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor. HDAC inhibitors have been shown to significantly increase hemoglobin F induction, which is well documented to improve outcomes in sickle cell disease. HDAC inhibitors are also known to potently inhibit cell-specific inflammation, which is a primary contributor to the debilitating effects of sickle cell disease. Given the relevance of these mechanisms of action in SCD, panobinostat may prove to contribute significantly to the management of SCD patients, a population in critical need of further effective treatment options.
Conditions
- Sickle Cell Disease
Interventions
panobinostatDrug
Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens: 1. 15 mg MWF 3 weeks on, 1 week off (if needed) 2. 15 mg MWF every week (starting dose) 3. 20 mg MWF 3 weeks on, 1 week off 4. 20 mg MWF every week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome MeasureTime frame: Days 1, 8, 15, 22, 29, 43, 57, 85, 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Augusta University
Augusta, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.